FDMT Stock Summary and Trading Ideas (4D Molecular Therapeutics | NASDAQ:FDMT)

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

4D Molecular Therapeutics trades on the NASDAQ stock market under the symbol FDMT.

As of March 6, 2026, FDMT stock price declined to $8.48 with 467,363 million shares trading.

FDMT has a beta of 1.40, meaning it tends to be more sensitive to market movements. FDMT has a correlation of 0.08 to the broad based SPY ETF.

FDMT has a market cap of $432.55 million. This is considered a Small Cap stock.

Last quarter 4D Molecular Therapeutics reported $90,000 in Revenue and -$1.01 earnings per share. This fell short of revenue expectation by $-555,800 and missed earnings estimates by -$.01.

In the last 3 years, FDMT traded as high as $36.25 and as low as $2.24.

The top ETF exchange traded funds that FDMT belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.

FDMT has outperformed the market in the last year with a return of +104.8%, while the SPY ETF gained +18.7%. However, in the most recent history, FDMT shares have underperformed the stock market with its stock returning -20.7% in the last 3 month period and -6.0% for the last 2 week period, while SPY has returned -1.7% and -2.5%, respectively.

FDMT support price is $8.24 and resistance is $9.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FDMT shares will trade within this expected range on the day.